Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorDurak Aras, Beyhan
dc.contributor.authorIşık, Sevgi
dc.contributor.authorÜsküdar Teke, Hava
dc.contributor.authorAslan, Abdulvahab
dc.contributor.authorYavaşoğlu, Filiz
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorDemirkan, Fatih
dc.contributor.authorÖzen, Hülya
dc.contributor.authorÇilingir, Oğuz
dc.contributor.authorİnci, Nur Sena
dc.contributor.authorGünden, Gülçin
dc.contributor.authorBulduk, Tuba
dc.contributor.authorErzurumluoğlu Gökalp, Ebru
dc.contributor.authorKocagil, Sinem
dc.contributor.authorArtan, Sevilhan
dc.contributor.authorAkay, Olga Meltem
dc.date.accessioned2022-06-14T06:46:33Z
dc.date.available2022-06-14T06:46:33Z
dc.date.issued2021en_US
dc.identifier.citationDurak Aras, B., Isik, S., Uskudar Teke, H., Aslan, A., Yavasoglu, F., Gulbas, Z., ... & Akay, O. M. (2021). Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?. Molecular Cytogenetics, 14(1), 1-7.en_US
dc.identifier.issn1755-8166
dc.identifier.urihttps://doi.org/10.1186/s13039-020-00522-1
dc.identifier.urihttps://hdl.handle.net/20.500.12933/1157
dc.description.abstractBackground Deletion of 13q14 [del(13q)] is the most common cytogenetic change (50%) in chronic lymphoblastic leukemia (CLL), and it is a good prognostic factor if it is detected as a sole aberration by FISH. However, it is observed the clinical course of CLL cases with del(13q) are quite heterogeneous and the responsible for this clinical heterogeneity has not been established yet. Some investigators suggest type II deletion (include RB1 gene) is associated with more aggressive clinical course. Also, it is suggested that the deletion burden and the deletion type have a prognostic effect. In this study, we aimed to investigate the effect of RB1 gene deletion, deletion burden and deletion type on overall survival (OS), disease stage and time to first treatment (TTFT) in patients with isolated del(3q). Sixty eight cases, detected isolated del(13q) were included in the study. Also, RB1 deletion was analyzed from peripheral blood of them using FISH. Results RB1 deletion was detected in 41% of patients, but there was no statistically significant difference between RB1 deletion and TTFT, stage and OS (p > 0.05). At same time, statistically significant difference was detected between high del(13q) (> 80%) and TTFT (p < 0.05). Conclusion The statistical analysis of our data regarding to the association between RB1 deletion and deletion type, TTFT, disease stage, and OS has not confirmed type II deletion or biallelic deletion cause poor prognosis. However, our data supports the deletion burden has a prognostic effect. More studies are needed to elucidate the cause of the clinical heterogeneity of CLL cases with del(13q).en_US
dc.language.isoengen_US
dc.publisherBioMed Central Ltden_US
dc.relation.isversionof10.1186/s13039-020-00522-1en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject13q deletionsen_US
dc.subjectB-CLLen_US
dc.subjectFISHen_US
dc.subjectPrognostic markeren_US
dc.subjectRB1 deletionsen_US
dc.titleWhich prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?en_US
dc.typearticleen_US
dc.authorid0000-0002-4017-4668en_US
dc.departmentAFSÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.contributor.institutionauthorYavaşoğlu, Filiz
dc.identifier.volume14en_US
dc.identifier.issue1en_US
dc.identifier.startpage1en_US
dc.identifier.endpage7en_US
dc.relation.journalMolecular Cytogeneticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster